4
项与 阿法依伯汀生物类似药(Blau Farmacêutica SA) 相关的临床试验Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.
Study in healthy volunteers to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as a single intravenous injection as well as safety, tolerability and the effects on certain blood values.
Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Compared to Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.
This is a prospective, randomized, multicenter, parallel, placebo-controlled, phase III study for evaluation of clinical efficacy and immunogenicity of drug Eritromax® - (rHuEPO Blau Farmacêutica S/A.) compared to Eprex® (Janssen-Cilag rHuEPO) for the treatment of patients with secondary anemia to chronic kidney disease (CKD), throughout the correction phase by assessing the change in hemoglobin levels.
100 项与 阿法依伯汀生物类似药(Blau Farmacêutica SA) 相关的临床结果
100 项与 阿法依伯汀生物类似药(Blau Farmacêutica SA) 相关的转化医学
100 项与 阿法依伯汀生物类似药(Blau Farmacêutica SA) 相关的专利(医药)
100 项与 阿法依伯汀生物类似药(Blau Farmacêutica SA) 相关的药物交易